Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus lenvatinib with or without cyclophosphamide in metastatic castration-resistant prostate cancer
ChiCTR2500110660Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of QL1706, lenvatinib and cyclophosphamide in castration-resistant prostate cancer (CRPC) (2 cohorts), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: radiographic progression-free survival. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
QL1706lenvatinibcyclophosphamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ChiCTR2500110660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110660.